VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Duke University
- Study ID
- NCT06249165
- Phase
- PHASE4
- Status
- Active Not Recruiting
Conditions
- Atherosclerotic Cardiovascular Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Inclisiran — DRUGInclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Study Details
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
Key Dates
- Start date
- Dec 16, 2024
- Status verified
- Oct 2025
- Primary completion
- Dec 31, 2026
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 130 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: InclisiranInclisiran + Usual Care
- No Intervention: Usual CareUsual Care
Primary Outcome Measure
Achievement of LDL-C targets [ Time Frame: Day 360 ]
Locations (23)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Univ. of Alabama - Birmingham | Birmingham | Alabama | 35205 | - |
| Univ. of California - Irvine | Orange | California | 92868 | - |
| San Francisco General Hospital | San Francisco | California | 94110 | - |
| Emory University | Atlanta | Georgia | 30324 | - |
| Wellstar Paulding | Hiram | Georgia | 30141 | - |
| Rush University | Chicago | Illinois | 60612 | - |
| University of Iowa | Iowa City | Iowa | 52242 | - |
| JHU - Suburban Hospital | Bethesda | Maryland | 20814 | - |
| Johns Hopkins | Columbia | Maryland | 21044 | - |
| Essentia Health | Duluth | Minnesota | 55805 | - |
| University of Missouri | Columbia | Missouri | 65212 | - |
| Washington University | St Louis | Missouri | 63110 | - |
| University of Nebraska | Omaha | Nebraska | 68198 | - |
| Heart House of NJ | Haddon Heights | New Jersey | 08035 | - |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | - |
| Duke University Medical Center | Durham | North Carolina | 27710 | - |
| Wake Forest University | Winston-Salem | North Carolina | 27157 | - |
| Temple University | Philadelphia | Pennsylvania | 19140 | - |
| Medical Univ. of South Carolina | Charleston | South Carolina | 29403 | - |
| Houston Methodist | Houston | Texas | 77030 | - |
| Baylor Scott & White - Waco | Waco | Texas | 76708 | - |
| University of Utah | Salt Lake City | Utah | 84132 | - |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Birmingham, AL
Related Studies
- A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase PatientsRecruiting · Intermountain Health Care, Inc. · Salt Lake City, Utah
- Pelacarsen Roll-over Extension ProgramPHASE3 · Recruiting · Novartis Pharmaceuticals · Birmingham, Alabama
- Polygenic Risk Score Implementation and Stratification for Managing Blood PressureRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPHASE3 · Recruiting · Amgen · Daphne, Alabama